RDY

NYSE Healthcare

Dr. Reddy's Laboratories Ltd Common Stock

Drug Manufacturers - Specialty & Generic

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

๐Ÿ“Š Market Data
Price$12.70
Volume1,520,039
Market Cap10.58B
Dividend Yield %0.65%
Beta0.260
RSI (14-Day)19.1 Oversold
200-Day MA$13.81
50-Day MA$13.59
52-Week High$15.67
52-Week Low$12.19
P/E Ratio23.09
Forward P/E19.34
Price / Book15.84
๐ŸŽฏ Investment Strategy Scores

RDY scores across each investment strategy. Higher is better for that strategy's goals.

๐Ÿ’ฐ Dividend Daddy 58/100โ–ผ -1
High dividend yield + low volatility
๐Ÿš€ Moon Shot 57/100โ–ฒ +17
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 93/100โ–ฒ +6
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 1/100โ–ผ -5
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (93/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐ŸŽˆ Over-Hyped (1/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find RDY in your text

Paste any article, transcript, or post โ€” the tool will extract RDY and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.